Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
B Cell
39%
Neoplasm
39%
microRNA 155
36%
Clustered Regularly Interspaced Short Palindromic Repeat
34%
Cancer
34%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
33%
Rituximab
26%
Vincristine
24%
microRNA
22%
International Prognostic Index
18%
Biological Marker
17%
Multiple Myeloma
17%
Programmed Cell Death
17%
Protein Tyrosine Kinase
17%
Mediator
17%
Cas9
17%
DNA Damage Response
17%
Cisplatin
17%
Somatics
17%
Diagnosis
13%
CD20
13%
Malignant Neoplasm
10%
Cyclophosphamide
10%
Doxorubicin
9%
B Lymphocyte Receptor
8%
Exome Sequencing
8%
T Cell
8%
Gene Expression
8%
Personalized Medicine
7%
Biopsy
7%
Prednisone
7%
Germinal Center
6%
Diffuse Large B-Cell Lymphoma Cell Line
5%
Follicular Lymphoma
5%
Skin Biopsy
5%
Targeted Therapy
5%
Symptomatic Treatment
5%
Proportional Hazards Model
5%
Copy Number Variation
5%
Combination Chemotherapy
5%
Principal Component Analysis
5%
Non-Hodgkin Lymphoma
5%
Immunotherapy
5%
False Positive Result
5%
Drug Effect
5%
Keyphrases
Notch3
17%
Hsp90 Inhibitor
17%
Vincristine-induced Neuropathy
17%
Bendamustine
17%
B-cell Linker
17%
Bruton's Tyrosine Kinase
17%
Linker Peptide
17%
CRISPR Interference (CRISPRi)
17%
Molecular Classification
17%
CRISPR-Cas9 Knockout
17%
Cisplatin Response
17%
Knockout Screen
17%
Evolutionary Events
17%
CDCA2
17%
Myeloid Cancer
17%
Somatic Variant Calling
17%
17-AAG
14%
Neuropathy Disability Score
12%
Long-term Remission
11%
ERCC6
7%
Platinum Drugs
5%
Relapsed Lymphoma
5%
High-grade non-Hodgkin Lymphoma
5%
Relapsed Tumor
5%
Branching Evolution
5%
Chlorambucil
5%
In Situ Lymphoma
5%
RELAP
5%
Tumor DNA
5%
Transformed Lymphoma
5%
Individual Evaluation
5%
WEE1
5%
Biochemistry, Genetics and Molecular Biology
B Cell
54%
Gene Signature
19%
B Lymphocyte Subpopulation
17%
T Cell
17%
MicroRNA
17%
Clonal Evolution
17%
Myeloid
17%
Bendamustine
17%
Proteomics
17%
Exon
17%
Cyclophosphamide
11%
Plasma Cell
7%
ERCC6
6%
XPA
6%
Genomics
5%
Exome Sequencing
5%
High Throughput Sequencing
5%
Solution and Solubility
5%
Clinical Decision Making
5%
Fibroblast
5%
DNA Repair
5%
Rituximab
5%